13F filer · CIK 1649339 ↗
Scion Asset Management
Reported value
$1.38B
+139% on the quarter before
Positions
8
7 new · 14 sold out
Top 10
100.0%
of the value
Est. gain
−$3.0M
on stocks held all quarter
Est. return
−25.1%
on those stocks since Q2 2025
Positions as of Sep 30, 2025, from Scion Asset Management's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q2 2025. Striped tiles are options.
Largest buys
Since Q2 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- PalantirPUT~$912.1MNew · 0.0% → 66.0%+5,000,000 underlying
- NvidiaPUT~$186.6MNew · 0.0% → 13.5%+1,000,000 underlying
- PfizerCALL~$152.9MNew · 0.0% → 11.1%+6,000,000 underlying
- HalliburtonCALL~$61.5MNew · 0.0% → 4.5%+2,500,000 underlying
- Molina Healthcare~$23.9MNew · 0.0% → 1.7%+125,000 shares
- Slm Corp~$13.3MNew · 0.0% → 1.0%+480,054 shares
- Bruker Corp~$13.1MNew · 0.0% → 1.0%+48,334 shares
- Lululemon Athletica~$8.9MAdded · 2.1% → 1.3%+50,000 shares
Largest sells
Since Q2 2025, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- UnitedHealth GroupCALL~$109.2MSold out · 18.9% → 0.0%−350,000 underlying
- Regeneron PharmaceuticalsCALL~$105.0MSold out · 18.2% → 0.0%−200,000 underlying
- Lululemon AthleticaCALL~$95.0MSold out · 16.4% → 0.0%−400,000 underlying
- MetaCALL~$73.8MSold out · 12.8% → 0.0%−100,000 underlying
- Estée Lauder Companies (The)CALL~$40.4MSold out · 7.0% → 0.0%−500,000 underlying
- JD.comCALL~$32.6MSold out · 5.6% → 0.0%−1,000,000 underlying
- AlibabaCALL~$28.4MSold out · 4.9% → 0.0%−250,000 underlying
- ASMLCALL~$20.0MSold out · 3.5% → 0.0%−25,000 underlying
- V F CorpCALL~$17.6MSold out · 3.0% → 0.0%−1,500,000 underlying
- Estée Lauder Companies (The)~$12.1MSold out · 2.1% → 0.0%−150,000 shares
Holdings
As of Sep 30, 2025. Changes are in shares against Jun 30, 2025, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| PalantirPUTCL A · shares New | 66.0% | $912.1M | — | ||||||||
| NvidiaPUTCOM · shares New | 13.5% | $186.6M | — | ||||||||
| PfizerCALLCOM · shares New | 11.1% | $152.9M | — | ||||||||
| HalliburtonCALLCOM · shares New | 4.5% | $61.5M | — | ||||||||
| Molina HealthcareCOM · shares New | 1.7% | $23.9M | — | ||||||||
| Lululemon AthleticaCOM · shares +100% · price −25.1% | 1.3% | $17.8M | −$3.0M | ||||||||
| Slm CorpCOM · shares New | 0.96% | $13.3M | — | ||||||||
| Bruker Corp6.375 PREF SER A · shares New | 0.95% | $13.1M | — | ||||||||
| Total · 8 positions | 100% | $1.38B | −$3.0M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q2 2025 to Q3 2025: 1 stocks held throughout, down $3.0M (−25.1%).
- Lululemon Athletica−$3.0M−25%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q3 2025 | Nov 3, 2025 | $1.38B+139% | SEC ↗ |
| Q2 2025 | Aug 14, 2025 | $578.3M+190% | SEC ↗ |
| Q1 2025 | May 15, 2025 | $199.2M+157% | SEC ↗ |
| Q4 2024 | Feb 14, 2025 | $77.4M−40% | SEC ↗ |
| Q3 2024 | Nov 14, 2024 | $129.8M+147% | SEC ↗ |
| Q2 2024 | Aug 14, 2024 | $52.5M−49% | SEC ↗ |
| Q1 2024 | May 15, 2024 | $103.5M+9% | SEC ↗ |
| Q4 2023 | Feb 16, 2024 (amended) | $94.6M−4% | SEC ↗ |
| Q3 2023 | Nov 14, 2023 | $99.0M−94% | SEC ↗ |
| Q2 2023 | Aug 14, 2023 | $1.74B+1,524% | SEC ↗ |
| Q1 2023 | May 15, 2023 | $106.9M+130% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $46.5M+13% | SEC ↗ |
| Q3 2022 | Nov 14, 2022 | $41.3M+1,148% | SEC ↗ |
| Q2 2022 | Aug 15, 2022 | $3.3M−98% | SEC ↗ |
| Q1 2022 | May 16, 2022 | $201.4M+170% | SEC ↗ |
| Q4 2021 | Feb 14, 2022 | $74.5M+78% | SEC ↗ |
| Q3 2021 | Nov 15, 2021 | $41.7M−98% | SEC ↗ |
| Q2 2021 | Aug 16, 2021 | $2.08B+54% | SEC ↗ |
| Q1 2021 | May 17, 2021 | $1.35B+503% | SEC ↗ |
| Q4 2020 | Feb 16, 2021 | $224.7M−32% | SEC ↗ |
| Q3 2020 | Nov 16, 2020 | $330.3M+5% | SEC ↗ |
| Q2 2020 | Aug 14, 2020 | $315.3M+267% | SEC ↗ |
| Q1 2020 | May 15, 2020 | $85.9M+4% | SEC ↗ |
| Q4 2019 | Feb 14, 2020 | $82.3M+38% | SEC ↗ |
| Q3 2019 | Nov 14, 2019 | $59.6M−36% | SEC ↗ |
| Q2 2019 | Aug 14, 2019 | $93.6M−5% | SEC ↗ |
| Q1 2019 | May 15, 2019 | $98.2M−5% | SEC ↗ |
| Q4 2018 | Feb 14, 2019 | $103.5M+193% | SEC ↗ |
| Q3 2016 | Nov 14, 2016 | $35.4M−22% | SEC ↗ |
| Q2 2016 | Aug 15, 2016 | $45.5M−11% | SEC ↗ |
| Q1 2016 | May 16, 2016 | $51.1M | SEC ↗ |